by Richard Daverman, PhD
January 27, 2014 -- Wanbang Biopharma in-licensed the China rights to develop a pre-clinical diabetes drug discovered by Sirona Biochem of Canada. Wanbang will make up to $9.5 million in upfront and milestone payments plus royalties. The drug is a member of the SGLT2 class of diabetes drugs that inhibit glucose reabsorption from the kidneys. Wanbang, a division of Fosun Pharma, is active in diabetes treatments. More details....
Stock Symbols: (TSX: SBM; OTCQS: SRBCF) (SHA: 600196; HK: 02196)
Help employers find you! Check out all the jobs and post your resume.
